Connect Biopharma Holdings (CNTB) Free Cash Flow (2024 - 2026)

Connect Biopharma Holdings has disclosed Free Cash Flow across 3 years of filings, most recently posting -$15.9 million for Q2 2026.

• In Q2 2026, Free Cash Flow fell 23.48% year-over-year to -$15.9 million; the TTM figure through Jun 2026 stood at -$60.8 million (down 57.03% YoY), while the FY2025 annual figure was -$51.8 million, down 112.67% from the prior year.
• Free Cash Flow came in at -$15.9 million for Q2 2026 at Connect Biopharma Holdings, up from -$16.0 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$592000.0 in Q1 2024 to a low of -$17.4 million in Q3 2025.
• Average Free Cash Flow over 3 years is -$10.8 million, with a median of -$12.2 million recorded in 2025.
• Year-over-year, Free Cash Flow tumbled 1595.95% in 2025 and fell 23.48% in 2026.
• Over 3 years, Free Cash Flow stood at -$2.6 million in 2024, then sank by 334.54% to -$11.4 million in 2025, then slumped by 39.21% to -$15.9 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$15.9 million in Q2 2026, -$16.0 million in Q1 2026, and -$11.4 million in Q4 2025.